TOP TEN perturbations for 39876_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39876_at
Selected probe(set): 201704_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39876_at (201704_at) across 6674 perturbations tested by GENEVESTIGATOR:
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-2.3064594Number of Samples:5 / 6
Experimental | colorectal adenoma study 2 |
Laser microdissected human adenoma sample. | |
Control | normal colon tissue |
Laser microdissected human colonic epithelial cells sample. |
HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)
Relative Expression (log2-ratio):2.170642Number of Samples:2 / 2
Experimental | HIV-associated neurocognitive disorder study 7 (normal) |
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART). | |
Control | HIV-associated neurocognitive disorder study 6 (normal) |
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART). |
prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)
Relative Expression (log2-ratio):2.158163Number of Samples:3 / 5
Experimental | prostate cancer study 8 (p. canc) |
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
Control | prostate cancer study 8 (psfmc) |
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-1.9482279Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.9042501Number of Samples:11 / 6
Experimental | ovarian tumor study 11 (low grade) |
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
Control | normal ovarian surface epithelial cell sample |
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
OPM-1 / MM1.S
Relative Expression (log2-ratio):-1.8752346Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.801671Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-1.7463589Number of Samples:4 / 8
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-1.7131758Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):-1.7105112Number of Samples:4 / 4
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |